Pharmacological studies over the past two decades have established acute actions of lithium on post-receptor targets in the brain. Lithium has been shown to inhibit adenylate cyclase (the enzyme that synthesizes cyclic AMP) and certain inositol phosphatases [involved in the phosphatidylinositol (PI) cycle] and to disrupt G-protein function. However, these acute effects cannot per se explain the therapeutic actions of lithium which require its chronic administration, and much less is known about the more long lasting changes that chronic exposure to lithium induces in brain. Although there have been a number of studies on the effects of chronic lithium on the cyclic AMP and PI systems, these investigations have been difficult to interpret mechanistically in that most reflect indirect measures of proteins which can be affected by many factors. The proposed pharmacological and neurochemical studies will directly examine the effects of chronic lithium and other antidepressant treatments on individual protein components of G-proteins and the cyclic AMP pathway to obtain a better understanding of drug action. In preliminary studies, we have shown that chronic lithium increases levels of mRNA and immuno-reactivity of type 1 and type 2 adenylate cyclase, and decreases levels of mRNA and immunoreactivity of the G- protein subunits, Gialpha1 and Gialpha2. These effects where observed under """"""""therapeutic"""""""" conditions (i.e., 4 weeks of treatment with serum lithium levels of about 1 mM), but not in response to short-term treatment or to chronic treatment with a lower dose of lithium. These intracellular adaptations would be expected to result in an up-regulated cyclic AMP system and could represent a homeostatic response to acute lithium inhibition of adenylate cyclase. In addition, we have found that chronic lithium alters the subcellular distribution of cyclic AMP- dependent protein kinase in rat cortex, with an apparent translocation of the lithium-induced alterations in the phosphorylation state of a number of specific phosphoproteins, including DARPP-32, a dopamine and cyclic AMP-regulated phosphoprotein of 32 kD. Similar effects were seen with certain other antidepressant treatments, but not with other classes of psychotropic drugs. The purpose of the proposed studies is to further characterize lithium and antidepressant regulation of these and related intracellular messengers with respect to the time course, dose dependence, and pharmacological and anatomical specificity of drug action. The proposed investigations, aimed at characterizing lithium- and antidepressant-induced adaptations in intracellular signal transduction pathways in rat brain, will provide a more complete understanding of the pharmacological and neurochemical actions exerted by long-term exposure to these drugs of the brain.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH051399-05
Application #
2675150
Study Section
Neuropharmacology and Neurochemistry Review Committee (NPNC)
Project Start
1994-09-30
Project End
1999-04-30
Budget Start
1998-05-01
Budget End
1999-04-30
Support Year
5
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Yale University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Monteggia, Lisa M; Heimer, Hakon; Nestler, Eric J (2018) Meeting Report: Can We Make Animal Models of Human Mental Illness? Biol Psychiatry 84:542-545
Muir, Jessie; Lorsch, Zachary S; Ramakrishnan, Charu et al. (2018) In Vivo Fiber Photometry Reveals Signature of Future Stress Susceptibility in Nucleus Accumbens. Neuropsychopharmacology 43:255-263
Hamilton, Peter J; Burek, Dominika J; Lombroso, Sonia I et al. (2018) Cell-Type-Specific Epigenetic Editing at the Fosb Gene Controls Susceptibility to Social Defeat Stress. Neuropsychopharmacology 43:272-284
Lorsch, Zachary S; Loh, Yong-Hwee Eddie; Purushothaman, Immanuel et al. (2018) Estrogen receptor ? drives pro-resilient transcription in mouse models of depression. Nat Commun 9:1116
Hultman, Rainbo; Ulrich, Kyle; Sachs, Benjamin D et al. (2018) Brain-wide Electrical Spatiotemporal Dynamics Encode Depression Vulnerability. Cell 173:166-180.e14
Tan, Aaron; Costi, Sara; Morris, Laurel S et al. (2018) Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder. Mol Psychiatry :
Kaufman, Joan; Wymbs, Nicholas F; Montalvo-Ortiz, Janitza L et al. (2018) Methylation in OTX2 and related genes, maltreatment, and depression in children. Neuropsychopharmacology 43:2204-2211
Hamilton, Peter J; Lim, Carissa J; Nestler, Eric J et al. (2018) Viral Expression of Epigenome Editing Tools in Rodent Brain Using Stereotaxic Surgery Techniques. Methods Mol Biol 1767:205-214
Hamilton, Peter J; Lim, Carissa J; Nestler, Eric J et al. (2018) Neuroepigenetic Editing. Methods Mol Biol 1767:113-136
Akil, Huda; Gordon, Joshua; Hen, Rene et al. (2018) Treatment resistant depression: A multi-scale, systems biology approach. Neurosci Biobehav Rev 84:272-288

Showing the most recent 10 out of 103 publications